Key facts
- It has raised $71.2M; the latest was Later Stage VC ($14.0M) in Oct 2025.
- Notable investors include Source Code Capital, Shun Xi Fund, Lapam Capital, Guolian Investment, Founder Hesheng Investment — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Cygnus Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Cygnus Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cygnus Bio
Operator of a biotechnology firm specializing in the research and development and industrialization of gene sequencing platforms. The company incorporates the use of gene sequencing technology to provide accurate, simple and fast overall biotech solutions, providing genetic engineers and gene therapy specialists with accurate data inputs and readings that help them conduct research experiments and draw conclusions on the same in an effective, efficient and error-free manner.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2015
- Employees
- 99
- Website
- cygnusbio.com/
- Ownership
- Privately Held (backing)
Cygnus Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cygnus Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cygnus Bio in its N-PORT filings yet. We sweep new filings monthly.